Third‐trimester erythrocytapheresis in pregnant patients with sickle cell disease

Abstract

These results suggest that erythrocytapheresis transfusions are beneficial in women with SCD who are in the third trimester of pregnancy. Given the decrease in transfusion risks, this therapy deserves further evaluation in future trials.